1. Home
  2. COHN vs PPBT Comparison

COHN vs PPBT Comparison

Compare COHN & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Company Inc.

COHN

Cohen & Company Inc.

HOLD

Current Price

$15.26

Market Cap

34.2M

Sector

Finance

ML Signal

HOLD

Logo Purple Biotech Ltd.

PPBT

Purple Biotech Ltd.

HOLD

Current Price

$0.68

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COHN
PPBT
Founded
1999
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.2M
7.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
COHN
PPBT
Price
$15.26
$0.68
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
40.3K
779.9K
Earning Date
11-04-2025
11-14-2025
Dividend Yield
6.48%
N/A
EPS Growth
6.29
N/A
EPS
2.50
N/A
Revenue
$185,475,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.19
N/A
Revenue Growth
107.11
N/A
52 Week Low
$6.10
$0.53
52 Week High
$20.70
$5.20

Technical Indicators

Market Signals
Indicator
COHN
PPBT
Relative Strength Index (RSI) 45.48 40.73
Support Level $17.78 $0.72
Resistance Level $20.70 $0.87
Average True Range (ATR) 1.61 0.05
MACD -0.37 -0.01
Stochastic Oscillator 2.01 15.60

Price Performance

Historical Comparison
COHN
PPBT

About COHN Cohen & Company Inc.

Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Share on Social Networks: